Comparative Pharmacology
Head-to-head clinical analysis: PHOSLO GELCAPS versus RENAGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLO GELCAPS versus RENAGEL.
PHOSLO GELCAPS vs RENAGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium acetate binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in feces, thereby reducing serum phosphate levels.
Sevelamer is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and reducing serum phosphate levels.
Oral: One to two capsules (668-1336 mg calcium acetate) three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL, maximum 4 capsules per meal.
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 1 tablet/capsule per meal based on serum phosphorus levels. Maintenance: typically 2-4 tablets/capsules per meal.
None Documented
None Documented
Not applicable; calcium is a physiologic ion with dynamic regulation; steady-state serum calcium is maintained by homeostatic mechanisms. In overdose, serum calcium half-life is approximately 3-4 hours.
Not applicable (non-absorbable polymer; systemic absorption <0.01%).
Primarily fecal as unabsorbed calcium; renal excretion accounts for <1% of absorbed dose proportional to glomerular filtration rate.
Renal: 0%; Fecal: >99% (as intact drug, due to non-absorbable polymer). Biliary: negligible.
Category C
Category C
Phosphate Binder
Phosphate Binder